Pfizer Inc. announced the appointment of Andrew Baum, M.D., as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will join Pfizer from Citi, where he served as Head of Global Healthcare, Managing Director Equity Research. In his new role, Dr. Baum will report to Chairman and Chief Executive Officer, Dr. Albert Bourla, and will be responsible for driving Pfizer’s long-term corporate strategic plan to maximise value for patients and shareholders.
“As we continue to advance impactful vaccines and therapies that deliver value for patients, health systems, and shareholders, Dr. Baum will be an important thought partner for me and my leadership team,” said Dr. Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “His rare profile, combining deep clinical and scientific knowledge with strong financial expertise, will bring fresh strategic insights into Pfizer’s business and portfolio.”
Dr. Baum brings over 30 years of experience to Pfizer, with a unique blend of clinical, scientific, and financial expertise. Prior to his role at Citi, he covered European Pharmaceuticals at Morgan Stanley for 14 years and earlier in his career, he was a practicing physician at the Royal National Orthopaedic Radcliffe Hospital in Oxford. Dr. Baum’s background in oncology and his role as the former co-chair of Immuno-Oncology 360° position him as a leader in advancing transformative therapies.
“I am thrilled to be joining Pfizer as Chief Strategy and Innovation Officer. I look forward to leveraging my prior experience to help Pfizer identify, accelerate, and deliver more breakthrough therapies with the power to transform patients’ lives,” said Andrew Baum, M.D.
In his new role, Dr. Baum will play a vital role in Pfizer’s portfolio analysis and prioritisation functions, business development activities, and strengthening partnerships with the biotech ecosystem. He will also chair Pfizer’s Portfolio Management Team, ensuring that the company brings forward vaccines and medicines that address unmet patient needs while achieving robust reimbursement and access.
